Anthony Neal

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 277 citations · Full text

Correlation of breast dose heterogeneity with breast size using 3D CT planning and dose-volume histograms

Anthony Neal, M. Torr, S.J. Helyer et al. · Radiotherapy and Oncology · 1995 · 145 citations

Computed Tomography, Breast Dose Heterogeneity, Health Sciences +13

Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3–07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study

Boon Chua, Emma Link, Ian Kunkler et al. · The Lancet · 2022 · 102 citations · Full text

Radiation Medicine, Breast Oncology, Radiation Therapy +11

Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial

Galina Velikova, Linda Williams, Sarah Willis et al. · The Lancet Oncology · 2018 · 80 citations · Full text

Quality Of Life, Surgical Oncology, Radiation Therapy +11

Evaluation of compensation in breast radiotherapy: a planning study using multiple static fields

Ellen M. Donovan, U. Johnson, Glyn Shentall et al. · International Journal of Radiation Oncology*Biology*Physics · 2000 · 74 citations

Adaptive Radiotherapy, Planning Study, Radiology +13